Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
Purpose of reviewThe review addresses the role of dolutegravir (DTG) in first-line therapy. In the era of test and treat, where United Nations AIDS Program and WHO have set the ambitious targets of 90/90/90, new efficacious, well tolerated, and simple therapeutic options are needed.Recent findingsDTG has been tested in large clinical trials in treatment-naïve patients, showing noninferiority to raltegravir and superiority compared with efavirenz and ritonavir-boosted darunavir, respectively. The main features of DTG are reviewed in this study, including efficacy, safety, high-resistance barrier, daily treatment schedule, and coformulation as single-tablet regimen. Use of DTG in special populations is also reviewed. Tolerability, with focus in neuropsychiatric disturbances is discussed in particular. DTG has shown high efficacy level, tested in males and females, has no limitations in patients with renal and/or hepatic impairment and is available as single drug (to be combined with two nucleoside reverse transcriptase inhibitors in fixed combinations) or as a single-tablet regimen combined with abacavir and lamivudine.SummaryDTG is an excellent candidate for initial therapy in HIV-infected patients. If safety of DTG in pregnant women are confirmed by ongoing studies, DTG might become the first option in WHO antiretroviral guidelines.
Current Opinion in HIV and Aids – Wolters Kluwer Health
Published: Jul 1, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.